PMV Pharma is a biotechnology company that develops precision therapies for the treatment of cancer. The company's lead product candidate, PC14586, is a small molecule inhibitor of the p53 tumor suppressor protein, which is mutated in over 50% of all cancers. PMV Pharma's mission is to develop therapies that target the underlying genetic drivers of cancer, with the goal of improving patient outcomes. The company was founded in 2013 and is headquartered in Louisville, Colorado.